Skip to content

Exelixis, Inc.

EXEL· NasdaqCore metricsCIK 939767

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -1.26%
Market cap
$17.03B
244.01M shares
Filings
1,039
$658.70M
Q3 2026+7.0% FY25 yoy
$218.10M
Q3 2026+50.1% FY25 yoy
$268.42M
Q3 2026+44.3% FY25 yoy
$828.73M
Q3 2026derived+30.4% FY25 yoy
$0.85
Q3 2026+58.0% FY25 yoy
$304.77M
Q3 2026+122.0% FY25 yoy
$17.03B
19.2×
6.8×
9.3×
6.82%
—

Twelve months to Oct 2, 2026 · derived

Price

$69.81+62.46%+$26.84past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$2.32BFY 2025
$2.32B0FY 2015FY 2020FY 2025
PeriodEndedValueKindSource trail
FY 20252026-01-02$2,320,126,000reported
FY 20242025-01-03$2,168,701,000reported
FY 20232023-12-29$1,830,208,000reported
FY 20222022-12-30$1,611,062,000reported
FY 20212021-12-31$1,434,970,000reported
FY 20202021-01-01$987,538,000reported
FY 20192020-01-03$967,775,000reported
FY 20182018-12-28$853,826,000reported
FY 20172017-12-29$452,477,000reported
FY 20162016-12-31$191,454,000reported
FY 20152016-01-01$37,172,000reported

Capital returns

Dividends and buybacks · FY2021 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$947.51M$947.51M—259.71M sh−7.2%108.2%
FY2024—$652.03M$652.03M—279.88M sh−7.7%97.1%
FY2023—$550.38M$550.38M—303.19M sh−6.4%187.9%
FY2022—$0.00$0.00—324.09M sh+1.5%0.0%
FY2021—$0.00$0.00—319.45M sh+2.4%0.0%

Segments

Revenue by Geography, FY2018 to FY2025FY2018U.S. · FY2018 · $632.93MEurope · FY2018 · $182.88MJapan · FY2018 · $38.02MFY2019U.S. · FY2019 · $770.24MEurope · FY2019 · $152.77MJapan · FY2019 · $44.76MFY2020U.S. · FY2020 · $752.89MEurope · FY2020 · $151.63MJapan · FY2020 · $83.02MFY2021U.S. · FY2021 · $1.09BEurope · FY2021 · $302.07MJapan · FY2021 · $43.50MFY2022U.S. · FY2022 · $1.41BEurope · FY2022 · $168.59MJapan · FY2022 · $28.73MFY2023U.S. · FY2023 · $1.65BEurope · FY2023 · $144.97MJapan · FY2023 · $39.49MFY2024U.S. · FY2024 · $1.82BEurope · FY2024 · $318.63MJapan · FY2024 · $27.08MFY2025U.S. · FY2025 · $2.14BEurope · FY2025 · $154.17MJapan · FY2025 · $25.59M
LineFY2025ShareChange
U.S.$2.14B92%+17.4%
Europe$154.17M6.6%−51.6%
Japan$25.59M1.1%−5.5%
Total$2.32B

From the 10-K filed Feb 10, 2026EXEL

Biological products, except diagnostic substances

Exelixis, Inc. is the 5th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Exelixis, Inc. · CIK 939767 · Engraved from SEC EDGAR